Common Side Effects of Lurbinectedin
Lurbinectedin (Zepzelca), used for small cell lung cancer, causes fatigue in 56% of patients and decreased appetite in 45%, based on clinical trial data from its FDA approval.[1] Sleep disturbances aren't listed as a top adverse event, but fatigue often disrupts rest.
Patient Reports on Appetite Changes
In real-world use, many patients note reduced appetite early in treatment, sometimes leading to weight loss. This stems from nausea (50% incidence) and general malaise, not direct hormonal effects. Some recover appetite after dose adjustments.[2]
Experiences with Sleep Issues
Fatigue affects over half of users, which can mean excessive daytime sleepiness or trouble sleeping at night due to discomfort. Insomnia appears less common (under 10% in trials), but anemia-related tiredness worsens it for some.[1][3]
How Long Do These Last?
Appetite suppression and fatigue peak in the first cycle, often easing by week 3-4. Persistent cases may need nutritional support or anti-nausea meds like ondansetron.[2]
Tips from Users and Doctors
Patients suggest small, frequent meals for appetite loss and short walks for sleep regulation. Oncologists monitor via bloodwork; report changes promptly to adjust dosing.[3]
[1]: FDA Label for Zepzelca
[2]: Drugs.com User Reviews
[3]: ClinicalTrials.gov Summary (NCT02454972)